Alterity Therapeutics Ltd ADR [NASDAQ: ATHE] closed the trading session at $4.5 on 2025-10-09. The day’s price range saw the stock hit a low of $4.16, while the highest price level was $4.65.
The stocks have a year to date performance of 239.62 percent and weekly performance of 7.40 percent. The stock has been moved at 63.04 percent over the last six months. The stock has performed -11.28 percent around the most recent 30 days and changed 15.09 percent over the most recent 3-months.
If compared to the average trading volume of 77.94K shares, ATHE reached to a volume of 4238029 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Alterity Therapeutics Ltd ADR [ATHE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATHE shares is $16.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATHE stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for Alterity Therapeutics Ltd ADR shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 03, 2025. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on December 12, 2024, representing the official price target for Alterity Therapeutics Ltd ADR stock.
The Price to Book ratio for the last quarter was 2.46, with the Price to Cash per share for the same quarter was set at 1.47.
ATHE stock trade performance evaluation
Alterity Therapeutics Ltd ADR [ATHE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.40. With this latest performance, ATHE shares dropped by -11.28% in over the last four-week period, additionally plugging by 63.04% over the last 6 months – not to mention a rise of 35.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATHE stock in for the last two-week period is set at 51.78, with the RSI for the last a single of trading hit 0.30, and the three-weeks RSI is set at 0.29 for Alterity Therapeutics Ltd ADR [ATHE]. The present Moving Average for the last 50 days of trading for this stock 4.80, while it was recorded at 4.33 for the last single week of trading, and 4.10 for the last 200 days.
Alterity Therapeutics Ltd ADR (ATHE) Capital Structure & Debt Analysis
According to recent financial data for Alterity Therapeutics Ltd ADR. ( ATHE), the Return on Equity (ROE) stands at -42.68%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -36.73%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Alterity Therapeutics Ltd ADR’s Return on Invested Capital (ROIC) is -28.36%, showcasing its effectiveness in deploying capital for earnings.
Alterity Therapeutics Ltd ADR (ATHE) Efficiency & Liquidity Metrics
Based on Alterity Therapeutics Ltd ADR’s (ATHE) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Alterity Therapeutics Ltd ADR (ATHE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Alterity Therapeutics Ltd ADR. (ATHE) effectively leverages its workforce, generating an average of -$877777.78 per employee. The company’s liquidity position is robust, with a Current Ratio of 12.98% and a Quick Ratio of 12.98%, indicating strong ability to cover short-term liabilities.
Alterity Therapeutics Ltd ADR [ATHE]: Institutional Ownership
There are presently around $1.23%, or 1.23%% of ATHE stock, in the hands of institutional investors. The top three institutional holders of ATHE stocks are: MORGAN STANLEY with ownership of 48395.0 shares, which is approximately 0.0013%. SUSQUEHANNA INTERNATIONAL GROUP, LLP, holding 23311.0 shares of the stock with an approximate value of $$41960.0 in ATHE stocks shares; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently with $$10724.0 in ATHE stock with ownership which is approximately 0.0002%.
